Literature DB >> 6971259

Adjuvant activities of quinonyl-N-acetyl muramyl dipeptides in mice and guinea pigs.

I Saiki, Y Tanio, M Yamawaki, M Uemiya, S Kobayashi, T Fukuda, H Yukimasa, Y Yamamura, I Azuma.   

Abstract

The adjuvant and tumor-suppressive activities of the quinonyl [2,3-dimethoxy-5-methyl-6-(9'-carboxynonyl)-1,4-benzoquinone (QS-10)] derivatives of N-acetyl muramyl dipeptides were examined. N-Acetyl muramyl-L-valyl-D-isoglutamine (MurNac-L-Val-D-isoGln), QS-10-MurNAc-L-Val-D-isoGln, and their methyl esters were shown to have potent adjuvant activity on the induction of delayed-type hypersensitivity to monoazobenzenarsonate-N-acetyl-L-tyrosine in guinea pigs and on the primary immune response against sheep erythrocytes in vitro; however, only QS-10-MurNAc-L-Val-D-isoGln methyl ester, i.e., QS-10-MurNAc-L-Val-D-Glu(OCH3)NH2 (quinonyl-MDP-66), was shown to be an active adjuvant for the induction of allogeneic killer T cells in mice and the suppression of tumor growth in syngeneic mice when it was administered as a suspension in phosphate-buffered saline. The effectiveness of the chain length of the quinonyl moiety in quinonyl-MDP-66 and the replacement of the L-valine residue with L-serine or L-threonine were also examined in comparison with the adjuvant and tumor-suppressive activities of quinonyl-MDP-66.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6971259      PMCID: PMC351759          DOI: 10.1128/iai.31.1.114-121.1981

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  20 in total

1.  Correlation of structure and adjuvant activity of N-acetyl muramyl-L-alanyl-D-isoglutamine (MDP), its derivatives and analogues. Anti-adjuvant and competition properties of stereoisomers.

Authors:  A Adam; M Devys; V Souvannavong; P Lefrancier; J Choay; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1976-09-07       Impact factor: 3.575

2.  Minimal structural requirements for adjuvant activity of bacterial peptidoglycan derivatives.

Authors:  F Ellouz; A Adam; R Ciorbaru; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-08-19       Impact factor: 3.575

3.  Adjuvant activity of monomeric bacterial cell wall peptidoglycans.

Authors:  A Adam; R Ciorbaru; F Ellouz; J F Petit; E Lederer
Journal:  Biochem Biophys Res Commun       Date:  1974-02-04       Impact factor: 3.575

4.  Primary immune response in cultures of spleen cells.

Authors:  J Marbrook
Journal:  Lancet       Date:  1967-12-16       Impact factor: 79.321

5.  Adjuvant and antitumor activities of Nocardia cell-wall skeletons.

Authors:  I Azuma; T Taniyama; M Yamawaki; K Sugimura; Y Yamamura
Journal:  Gan       Date:  1976-10

6.  Studies of allograft immunity in mice. I. Induction, development and in vitro assay of cellular immunity.

Authors:  K T Brunner; J Mauel; H Rudolf; B Chapuis
Journal:  Immunology       Date:  1970-04       Impact factor: 7.397

7.  Adjuvant activity of 6-O-mycoloyl-N-acetylmuramuyl-L-alanyl-D-isoglutamine.

Authors:  Y Yamamura; I Azuma; K Sugimura; M Yamawaki; M Uemiya
Journal:  Gan       Date:  1976-12

8.  Adjuvant activity of mycobacterial fractions: adjuvant activity of synthetic N-acetylmuramyl-dipeptide and the related compounds.

Authors:  I Azuma; K Sugimura; T Taniyama; M Yamawaki; Y Yamamura
Journal:  Infect Immun       Date:  1976-07       Impact factor: 3.441

9.  Comparison between macrophage activation and enhancement of nonspecific resistance to tumors by mycobacterial immunoadjuvants.

Authors:  D Juy; L Chedid
Journal:  Proc Natl Acad Sci U S A       Date:  1975-10       Impact factor: 11.205

10.  Immunoadjuvant activities of synthetic N-acetyl-muramyl-peptides or -amino acids.

Authors:  S Kotani; Y Watanabe; F Kinoshita; T Shimono; I Morisaki
Journal:  Biken J       Date:  1975-06
View more
  9 in total

1.  Adjuvant activity of carbohydrate analogs of N-acetylmuramyl-L-alanyl-D-isoglutamine on the induction of delayed-type hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs.

Authors:  I Azuma; H Okumura; I Saiki; M Kiso; A Hasegawa; Y Tanio; Y Yamamura
Journal:  Infect Immun       Date:  1981-09       Impact factor: 3.441

2.  Adjuvant activity of 6-amino-6-deoxy-muramyldipeptides and their acylamino derivatives on the induction of delayed hypersensitivity to azobenzenearsonate-N-acetyl-L-tyrosine in guinea pigs.

Authors:  I Azuma; H Okumura; I Saiki; Y Tanio; M Kiso; A Hasegawa; Y Yamamura
Journal:  Infect Immun       Date:  1981-06       Impact factor: 3.441

3.  Enhancement of resistance to Escherichia coli infection in mice by dihydroheptaprenol, a synthetic polyprenol derivative.

Authors:  S Araki; K Kagaya; K Kitoh; M Kimura; Y Fukazawa
Journal:  Infect Immun       Date:  1987-09       Impact factor: 3.441

4.  Effect of quinonyl-N-acetyl muramyl dipeptide on immune responses in tumor-bearing mice.

Authors:  I Saiki; Y Tanio; K I Yamamoto; Y Yamamura; I Azuma
Journal:  Infect Immun       Date:  1983-01       Impact factor: 3.441

5.  Activation of macrophages by quinonyl-N-acetylmuramyl dipeptide.

Authors:  I Saiki; Y Tokushima; K Nishimura; Y Yamamura; I Azuma
Journal:  Infect Immun       Date:  1983-05       Impact factor: 3.441

6.  Stimulation of chemiluminescence by synthetic muramyl dipeptide and analogs.

Authors:  K N Masihi; I Azuma; W Brehmer; W Lange
Journal:  Infect Immun       Date:  1983-04       Impact factor: 3.441

7.  Activation of mouse peritoneal adherent cells with N-acyl muramyl dipeptide derivatives.

Authors:  K Nishimura; H Okumura; I Saiki; H Okuyama; I Azuma
Journal:  Infect Immun       Date:  1985-03       Impact factor: 3.441

8.  Immunomodulatory and erythropoietic effects of aqueous extract of the fruits of Solanum torvum Swartz (Solanaceae).

Authors:  George A Koffuor; Patrick Amoateng; Terrick A Andey
Journal:  Pharmacognosy Res       Date:  2011-04

Review 9.  Harnessing the untapped potential of nucleotide-binding oligomerization domain ligands for cancer immunotherapy.

Authors:  Sanja Nabergoj; Irena Mlinarič-Raščan; Žiga Jakopin
Journal:  Med Res Rev       Date:  2018-12-13       Impact factor: 12.944

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.